Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FES | P07332 | 3/20 | 0.84 |
| ▸ | FLT3 | P36888 | 3/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 15/20 | 0.71 |
| ▸ | TTK | P33981 | 4/20 | 0.67 |
| ▸ | INSR | P06213 | 4/20 | 0.67 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.67 |
| ▸ | PLK4 | O00444 | 2/20 | 0.67 |
| ▸ | GAK | O14976 | 2/20 | 0.67 |
| ▸ | ERN1 | O75460 | 2/20 | 0.67 |
| ▸ | STK10 | O94804 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | YES1 | P07947 | 2/20 | 0.67 |
| ▸ | IGF1R | P08069 | 2/20 | 0.67 |
| ▸ | HCK | P08631 | 2/20 | 0.67 |
| ▸ | ROS1 | P08922 | 2/20 | 0.67 |
| ▸ | FER | P16591 | 2/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953410 | 0.94 | FES (0.82) | FESFLT3ALKTTKINSR | |
| SCHEMBL3954048 | 0.91 | FES (1.00) | FESFLT3ALKTTKINSR | |
| SCHEMBL3959279 | 0.89 | FES (0.84) | FESFLT3ALKTTKINSR | |
| SCHEMBL14866148 | 0.88 | ALK (0.77) | FESFLT3ALKTTKINSR | |
| SCHEMBL3952863 | 0.87 | ALK (0.75) | FESFLT3ALKTTKINSR | |
| SCHEMBL4056732 | 0.86 | FES (0.69) | FESFLT3ALKTTKINSR | |
| SCHEMBL13394913 | 0.85 | ALK (0.74) | FESFLT3ALKTTKINSR | |
| SCHEMBL22985878 | 0.85 | FES (0.61) | FESFLT3ALKTTKINSR | |
| SCHEMBL18843559 | 0.84 | ALK (0.87) | FESFLT3ALKTTKINSR | |
| SCHEMBL3958582 | 0.84 | FES (0.87) | FESFLT3ALKTTKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | FES 4037/4885FLT3 4356/4885ALK 4666/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | FES 4037/4885FLT3 4356/4885ALK 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.